Ohio Innovation Fund

Ohio Innovation Fund

A venture capital firm in Ohio that focuses on providing venture capital and expertise to early stage companies.

Ohio Innovation Fund is a venture capital firm in Ohio that focuses on providing venture capital and expertise to early stage companies. Founded 2016 in Columbus, Ohio, United States, it invests in early stage ventures. Its portfolio companies include S4 Medical, EmployStream, eFuse, Complion, Stirling Ultracold, DAtAnchor, and Enable Injections. As of April 2020, Ohio Innovation Fund has made 24 investments. Their most recent investment was on February 17, 2020 with S4 Medical. Ohio Innovation Fund has raised a single venture fund, Ohio Innovation Fund. The company invests in technology and life sciences companies that are based in, or have connections with, the state of Ohio.

Timeline

Funded Companies

Company
Description
Industry
Website
Location
Immuta

Immuta is a Boston-based provider of a cloud-native data governance platform for organizations to automate data access control, security and privacy compliance.

Genesis is a company that provides integrated biomagnetic solutions.

ScriptDrop provides prescription delivery to pharmacies and patients through a nationwide network of couriers.

Spirometrix is a Pleasanton, California-based diagnostic tools company focused on the research and development of breath analyzers and founded in 2011 by SOLOMON SSENYANGE.

Eccrine Systems is a Cincinnati-based company founded in 2013 by Robert Beech.

6 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Bill Baumel

Managing Director

Faith Voinovic

Associate

Jill Raderstorf

Partner

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

DAtAnchor

Enable Injections

S4 Medical

News

Title
Author
Date
Publisher
Description
BioSpace
May 4, 2020
BioSpace
Today marks the launch of Clarametyx Biosciences Inc ., ("Clarametyx") a preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms. The company's lead candidate, CMTX-001, is a huma

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.